WebDoctor Encyclopedia

Gastrointestinal

Small bowel & anus

Encyclopedia entries in Small bowel & anus.

  1. Small bowel & anus

    Anal squamous cell carcinoma

    Anal squamous cell carcinoma is an HPV-related cancer of the anal canal. This entry covers the Nigro chemoradiation approach and staging.

    3,702 words

  2. Small bowel & anus

    Small-bowel adenocarcinoma

    Small-bowel adenocarcinoma is a rare small-intestine cancer. This entry covers Crohn, Lynch, coeliac disease, and treatment approaches.

    4,498 words

Key Practice Points

  • Rarity: Small bowel tumors (SBTs) account for < 3% of all GI neoplasms and < 1% of GI cancer deaths, despite the small bowel comprising 75% of GI tract length and 90% of mucosal surface area.
  • Histologic Diversity: The “Big Four” histologies of the small bowel are Adenocarcinoma, Neuroendocrine Tumors (NETs), Lymphoma, and GIST. Anal canal tumors are predominantly Squamous Cell Carcinoma (SCC) driven by HPV.
  • Diagnostic Delay: Average time to diagnosis for SBTs is 6–12 months due to non-specific symptoms and anatomical inaccessibility.
  • Paradigm Shift in Anal Cancer: Chemoradiation (Nigro protocol) remains standard for localized anal SCC, but immunotherapy (PD-1 inhibitors) has transformed metastatic disease management.
  • Molecular Profiling: Essential for SBTs (MMR/MSI status, NTRK fusions, KIT/PDGFRA mutations) and increasingly relevant in anal cancer.

Small Bowel Tumors (SBTs)

1. Epidemiology & Risk Factors

  • Incidence: Rising (approx. 12,000 new cases/year in US), partly due to increased cross-sectional imaging and capsule endoscopy.
  • Median Age: 60–70 years (Adenocarcinoma); younger for NETs/Lymphoma/GIST.
  • Risk Factors:
    • Adenocarcinoma: Crohn’s disease (ileum, relative risk 20–30x), Celiac disease, Familial Adenomatous Polyposis (FAP), Lynch Syndrome (LS), Peutz-Jeghers Syndrome.
    • NETs: MEN1, NF1, VHL syndrome.
    • Lymphoma: Immunosuppression (HIV, post-transplant), Celiac disease (Enteropathy-associated T-cell Lymphoma – EATL).
    • GIST: KIT/PDGFRA mutations (sporadic), Carney Triad, NF1.

2. Histologic Classification & Distribution

Histology % of SBTs Most Common Site Key Molecular Features
Adenocarcinoma 30–40% Duodenum (50%), Jejunum, Ileum MSI-H/dMMR (~20%), KRAS, TP53, APC, SMAD4; HER2 amp (2-5%), NTRK fusions (<1%)
Neuroendocrine Tumor (NET) 30–40% Ileum (terminal), Appendix MEN1, DAXX/ATRX, TERT; Graded by Ki-67 (G1/G2/G3)
GIST 15–20% Jejunum/Ileum > Duodenum KIT (exon 11, 9), PDGFRA (exon 18 D842V), SDH-deficient (pediatric/young adult)
Lymphoma 10–20% Ileum (MALT, DLBCL); Jejunum (EATL) EBV+ (post-transplant); JAK/STAT mutations (EATL)
Other <5% Variable Sarcomas (Leiomyosarcoma), Metastases (Melanoma, Lung, Breast)

3. Clinical Presentation

  • Classic Triad (Rare): Obscure GI bleeding, Abdominal pain, Weight loss.
  • Adenocarcinoma: Chronic blood loss anemia, vague epigastric/periumbilical pain, early satiety, obstruction (late sign).
  • NET: Carcinoid syndrome (flushing, diarrhea, valvular heart disease) only with liver mets; otherwise silent or obstructive.
  • GIST: GI bleeding (ulceration), abdominal mass, incidental finding.
  • Lymphoma: “B symptoms” (fever, night sweats), perforation risk (EATL), malabsorption.

4. Diagnostic Workup (Algorithm)

  1. Laboratory: CBC, CMP, Iron studies, CEA, CA 19-9, Chromogranin A, 5-HIAA (24-hr urine), LDH (Lymphoma), Fecal Immunochemical Test (FIT).
  2. Cross-Sectional Imaging (First Line): CT Enterography (CTE) or MR Enterography (MRE). Gold standard for mural thickening, mesenteric involvement, mesenteric lymphadenopathy (“sandwich sign” for lymphoma), and vascular encasement.
  3. Endoscopic Evaluation:
    • Push Enteroscopy / Device-Assisted Enteroscopy (DBE/SBE): Biopsy proximal/mid lesions; tattooing; dilation of strictures.
    • Capsule Endoscopy (VCE): Gold standard for mucosal lesions/occult bleeding; Contraindicated if obstruction suspected (retention risk ~1-2%).
  4. Tissue Diagnosis: Mandatory before systemic therapy. Core needle biopsy preferred over FNA for lymphoma/GIST (architecture + IHC).

5. Staging (AJCC 8th Edition / TNM)

  • Adenocarcinoma/GIST/NET: Standard TNM (T1-T4, N0-N2, M0-M1).
  • Lymphoma: Lugano Classification (Ann Arbor modified) + PET-CT (FDG-avid).
  • Critical Distinction: Nodal status is the single most important prognostic factor for Adenocarcinoma.

6. Management by Histology

A. Adenocarcinoma

Stage Standard of Care Key Nuances
Resectable (I-III) En bloc Surgical Resection (Segmental resection + wide mesenteric lymphadenectomy; ≥12 nodes). Duodenal tumors: Pancreaticoduodenectomy (Whipple) vs. Organ-sparing (segmental duodenectomy) for distal/ampullary.
Stage III (Node+) Adjuvant Chemotherapy (Category 1 for Colon, extrapolated). CAPOX or FOLFOX x 6 months. PRODIGE 33 trial: No OS benefit for adjuvant FOLFOX in unselected SB adenocarcinoma, but subset benefit in Node+. Discuss risk/benefit.
Metastatic (IV) Systemic Therapy (Extrapolated from CRC). FOLFOX/CAPOX ± Bevacizumab or FOLFIRI ± Bevacizumab. MSI-H/dMMR: Pembrolizumab/Dostarlimab (1st line preferred). NTRK fusion: Larotrectinib/Entrectinib. HER2+: Trastuzumab + Chemo (trastuzumab deruxtecan emerging).
Palliative Obstruction Surgery (bypass/stent) > Endoscopic stenting (duodenum).

B. Neuroendocrine Tumors (NETs)

  • Localized (G1/G2): Surgical resection (R0) + Lymphadenectomy. Node dissection mandatory even for small (<1cm) ileal NETs due to high nodal metastasis rate.
  • Metastatic/Unresectable:
    • Somatostatin Analogs (SSA): Octreotide LAR / Lanreotide (PROMID/CLARINET trials) – Anti-tumor effect + Symptom control.
    • Progressive Disease: Peptide Receptor Radionuclide Therapy (PRRT – Lu-177 DOTATATE) (NETTER-1 trial); Everolimus (RADIANT-4); Chemotherapy (CAPTEM) for High Grade (G3) or Ki-67 >10%.
  • Carcinoid Syndrome: SSA first line; Telotristat Ethyl for refractory diarrhea.

C. GIST

  • Resectable: Surgery (R0, no lymphadenectomy needed unless nodes clinically +). Rupture = High Risk.
  • Adjuvant Imatinib: 3 years standard for High Risk (Tumor size >5cm, Mitotic count >5/5mm², Rupture). Consider 5 years for very high risk.
  • Neoadjuvant Imatinib: For borderline resectable / organ preservation (rectal/GI tract), 6–12 months pre-op.
  • Advanced/Metastatic:
    • 1st Line: Imatinib 400mg/day (800mg for KIT Exon 9).
    • 2nd Line: Sunitinib.
    • 3rd Line: Regorafenib.
    • 4th Line: Ripretinib (INVICTUS trial) or Avapritinib (specifically for PDGFRA D842V mutation – 1st line standard).
    • SDH-deficient GIST: Imatinib resistant; consider clinical trials / SDH inhibitors.

D. Lymphoma

  • Gastric/Intestinal MALT / DLBCL: R-CHOP (or R-CVP) ± Radiation (involved site RT for bulky disease).
  • EATL (Type I): CHOP-like regimens (poor prognosis); Autologous SCT consolidation in CR1.
  • IMETL (Indolent T-cell): Watch-and-wait or localized therapy.
  • Surgery: Only for perforation, obstruction, or diagnostic biopsy. Avoid “second-look” laparotomy.

Anal Canal Tumors

1. Epidemiology & Etiology

  • Incidence: Rising (~9,000 cases/year US); Female predominance; Peak age 60s.
  • HPV Association: > 90% SCC are HPV-positive (Type 16, 18). p16 IHC used as surrogate.
  • Risk Factors: Receptive anal intercourse, HIV/MSM (incidence 80x general pop), Immunosuppression, Cervical/Vulvar cancer history, Smoking.

2. Anatomy & Staging (AJCC 8th Ed.)

  • Anal Canal: Anal verge → Dentate line → Anorectal ring (2–4 cm).
  • Perianal Skin: Hair-bearing skin 5cm from verge. Staged as Skin (SCC) if >5cm, Anal Canal if ≤5cm.
  • Staging: Clinical exam (DRE, Anoscopy) + MRI Pelvis (T staging, nodes) + PET-CT or CT Chest/Abd/Pelvis (M staging). Inguinal nodes = Regional (N1b) – Must be palpated/imaged.

3. Clinical Presentation

  • Rectal bleeding (50%), Pain/tenesmus, Palpable mass, Pruritus, Discharge, Fecal incontinence (sphincter invasion).
  • Inguinal Lymphadenopathy: Present in 10–20% at diagnosis; distinguish reactive vs. metastatic (FNA/Core biopsy).

4. Management: The Organ Preservation Paradigm

A. Localized Disease (Stage I–III) – Definitive Chemoradiation (CRT)

  • Standard: Nigro Protocol (Mitomycin C + 5-FU) + RT (45–50.4 Gy / 25–28 fractions).
  • Modern Evolution: OMIT Mitomycin C (MMC) for T1-T2N0 (RTOG 0529 / ACT II trials) → 5-FU/Capecitabine + Cisplatin or 5-FU/Capecitabine alone reduces acute toxicity (neutropenia, dermatitis) without compromising DFS.
  • Radiation Technique: IMRT/VMAT mandatory to spare bowel, bladder, femoral heads, perineal skin, genitalia.
  • Boost: 9–14 Gy to primary/Gross nodes (often simultaneous integrated boost – SIB).
  • Response Assessment: Clinical exam at 8–12 weeks post-CRT. Biopsy only if persistent gross tumor. Complete clinical response (cCR) = 80–90%.

B. Salvage Surgery (Abdominoperineal Resection – APR)

  • Indications: Persistent/recurrent tumor at primary site after CRT (biopsy proven), Sphincter dysfunction/fistula, Patient preference.
  • Lymph Node Salvage: Inguinal lymphadenectomy (superficial ± deep) for persistent nodal disease (morbidity: lymphedema, wound breakdown).

C. Metastatic/Recurrent Disease (Stage IV)

  • 1st Line: Immunotherapy (PD-1 Inhibitors).
    • Pembrolizumab / Nivolumab / Retifanlimab / Toripalimab: ORR ~15-24%, Durable responses, better QoL vs chemo. Preferred 1st line (NCCN Category 1).
  • Subsequent Lines: Platinum-based chemo (Cisplatin/Carboplatin + 5-FU/Paclitaxel), Clinical trials.
  • Palliative RT: For bleeding, pain, obstruction.

D. Special Populations

  • HIV+: Same CRT protocol if CD4 > 200; dose-reduce chemo if CD4 < 200; ART adherence critical.
  • Perianal (Anal Margin) SCC: Wide Local Excision (WLE) for T1N0 (<2cm, well-mod diff, no LVI). CRT for T2+ or high-risk T1.

Surveillance & Survivorship

Tumor Type Surveillance Protocol (Post-Curative Intent)
SB Adenocarcinoma H&P, CEA/CA19-9 q 3–6 mo x 2 yrs, then q 6 mo x 3 yrs. CT CAP q 6–12 mo x 3 yrs. Colonoscopy at 1 yr, then q 3–5 yrs (metachronous CRC risk). CTE/MRE if high risk.
SB NET (G1/G2) CGA, 5-HIAA, CTE/MRE or Ga-68 DOTATATE PET/CT q 6–12 mo (indefinite).
GIST CT Abd/Pelvis q 3–6 mo x 5 yrs, then annually (recurrence peaks at 2 yrs, late recur >5 yrs).
SB Lymphoma PET-CT at end of treatment. CT q 6 mo x 2 yrs, then annually x 3-5 yrs (late relapse possible).
Anal SCC DRE + Anoscopy q 3–4 mo x 2 yrs, q 6 mo x 3 yrs, then annually. Assess inguinal nodes. HPV vaccination (Gardasil 9) recommended up to age 45. Anal cytology/HPV testing in high-risk (HIV+).

Multidisciplinary Team (MDT) Coordination

  • Essential Members: Surgical Oncologist (Colorectal/HPB), Medical Oncologist, Radiation Oncologist, Radiologist (GI expertise), Pathologist (GI/Soft tissue expertise), Nuclear Medicine (NETs/GIST), Genetic Counselor (Lynch, MEN1, SDH), Enterostomal Therapist, Palliative Care, Nutrition.

Quick Reference: “Don’t Miss” Diagnoses

  1. Crohn’s vs. Ileal Adenocarcinoma/Lymphoma: Stricture in long-standing Crohn’s → Biopsy aggressively (multiple deep biopsies); consider PET-CT. Surgery often required for definitive dx.
  2. Celiac Disease + New Symptoms: EATL (Type II RCD). Capsule endoscopy + CT enterography + Flow cytometry on biopsies.
  3. “Hemorrhoids” in MSM/HIV+: Anal SCC / HSIL. Perform High-Resolution Anoscopy (HRA).
  4. GIST with PDGFRA D842V: Primary resistance to Imatinib. Start Avapritinib immediately.
  5. NET with Carcinoid Syndrome: Tricuspid/Pulmonic Valvular Disease → Echo screening mandatory pre-surgery (anesthesia risk).

References

  1. NCCN Guidelines: Small Bowel Adenocarcinoma (v.2.2024), GIST (v.1.2024), Neuroendocrine Tumors (v.2.2024), Anal Carcinoma (v.2.2024).
  2. AJCC Cancer Staging Manual, 8th Edition.
  3. Overman MJ, et al. Lancet Oncol. 2017 (Pembrolizumab MSI-H).
  4. Glimelius B, et al. Lancet Oncol. 2022 (Immunotherapy Anal Cancer).
  5. Demetri GD, et al. Lancet. 2022 (Ripretinib INVICTUS); NEJM. 2023 (Avapritinib NAVIGATOR).
  6. Strosberg J, et al. NEJM. 2017 (NETTER-1 Lu-177).
  7. RTOG 0529 / ACT II / PLATO trials: Anal Cancer de-escalation.
  8. ESMO Clinical Practice Guidelines: Small Bowel Neoplasms (2023), Anal Cancer (2022).

Disclaimer: This article is intended for educational use by licensed healthcare professionals. It does not replace clinical judgment or institutional protocols. Treatment algorithms evolve rapidly; verify current FDA approvals and NCCN/ESMO guideline versions prior to clinical application.